Prognostic impact of cytogenetic abnormalities in adult patients with Philadelphia chromosome-negative ALL who underwent an allogeneic transplant

for the Kanto Study Group for Cell Therapy (KSGCT)

Research output: Contribution to journalArticle

Abstract

Although cytogenetic abnormalities at diagnosis are recognized as an important prognostic factor in patients with Philadelphia chromosome (Ph)-negative acute lymphoblastic leukemia (ALL), the prognostic impact has not been evaluated in allogeneic stem cell transplant (allo-SCT) recipients. Thus, we assessed 373 Ph-negative ALL patients who underwent allo-SCT. The high-risk (HR) group included those with t(4;11), t(8;14), low hypodiploidy, and complex karyotype, and the standard risk (SR) group included all other karyotypes. Among the 204 patients who underwent a transplant during the first remission (167 in the SR group and 37 in the HR group), the overall survival (OS) rates were similar between these groups (64.1% vs. 80.0% at 5 years, respectively; p = 0.12). Conversely, among the 106 patients who underwent a transplant while not in remission (84 in the SR group and 22 in the HR group), patients in the SR group showed a significantly superior OS rate compared to the HR group (15.4% vs. 4.5% at 5 years, respectively; p = 0.022). These results suggested that treatment outcomes of Ph-negative ALL patients with HR cytogenetic abnormalities may improve following allo-SCT, especially in the first remission. Innovative transplant approaches are warranted in patients who are not in remission.

Original languageEnglish
JournalBone Marrow Transplantation
DOIs
Publication statusPublished - 2019 Jan 1

Fingerprint

Philadelphia Chromosome
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Chromosome Aberrations
Transplants
Stem Cells
Karyotype
Survival Rate

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Prognostic impact of cytogenetic abnormalities in adult patients with Philadelphia chromosome-negative ALL who underwent an allogeneic transplant. / for the Kanto Study Group for Cell Therapy (KSGCT).

In: Bone Marrow Transplantation, 01.01.2019.

Research output: Contribution to journalArticle

@article{66de5624aefb48958c34b8b64174ba76,
title = "Prognostic impact of cytogenetic abnormalities in adult patients with Philadelphia chromosome-negative ALL who underwent an allogeneic transplant",
abstract = "Although cytogenetic abnormalities at diagnosis are recognized as an important prognostic factor in patients with Philadelphia chromosome (Ph)-negative acute lymphoblastic leukemia (ALL), the prognostic impact has not been evaluated in allogeneic stem cell transplant (allo-SCT) recipients. Thus, we assessed 373 Ph-negative ALL patients who underwent allo-SCT. The high-risk (HR) group included those with t(4;11), t(8;14), low hypodiploidy, and complex karyotype, and the standard risk (SR) group included all other karyotypes. Among the 204 patients who underwent a transplant during the first remission (167 in the SR group and 37 in the HR group), the overall survival (OS) rates were similar between these groups (64.1{\%} vs. 80.0{\%} at 5 years, respectively; p = 0.12). Conversely, among the 106 patients who underwent a transplant while not in remission (84 in the SR group and 22 in the HR group), patients in the SR group showed a significantly superior OS rate compared to the HR group (15.4{\%} vs. 4.5{\%} at 5 years, respectively; p = 0.022). These results suggested that treatment outcomes of Ph-negative ALL patients with HR cytogenetic abnormalities may improve following allo-SCT, especially in the first remission. Innovative transplant approaches are warranted in patients who are not in remission.",
author = "{for the Kanto Study Group for Cell Therapy (KSGCT)} and Hiroaki Shimizu and Noriko Doki and Heiwa Kanamori and Toru Sakura and Takehiko Mori and Shinichiro Machida and Satoshi Takahashi and Chikako Ohwada and Shin Fujisawa and Shingo Yano and Maki Hagihara and Yoshinobu Kanda and Masahiro Onoda and Moritaka Gotoh and Shinichi Kako and Jun Taguchi and Kensuke Usuki and Nobutaka Kawai and Nobuyuki Aotsuka and Shinichiro Okamoto",
year = "2019",
month = "1",
day = "1",
doi = "10.1038/s41409-019-0585-2",
language = "English",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Prognostic impact of cytogenetic abnormalities in adult patients with Philadelphia chromosome-negative ALL who underwent an allogeneic transplant

AU - for the Kanto Study Group for Cell Therapy (KSGCT)

AU - Shimizu, Hiroaki

AU - Doki, Noriko

AU - Kanamori, Heiwa

AU - Sakura, Toru

AU - Mori, Takehiko

AU - Machida, Shinichiro

AU - Takahashi, Satoshi

AU - Ohwada, Chikako

AU - Fujisawa, Shin

AU - Yano, Shingo

AU - Hagihara, Maki

AU - Kanda, Yoshinobu

AU - Onoda, Masahiro

AU - Gotoh, Moritaka

AU - Kako, Shinichi

AU - Taguchi, Jun

AU - Usuki, Kensuke

AU - Kawai, Nobutaka

AU - Aotsuka, Nobuyuki

AU - Okamoto, Shinichiro

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Although cytogenetic abnormalities at diagnosis are recognized as an important prognostic factor in patients with Philadelphia chromosome (Ph)-negative acute lymphoblastic leukemia (ALL), the prognostic impact has not been evaluated in allogeneic stem cell transplant (allo-SCT) recipients. Thus, we assessed 373 Ph-negative ALL patients who underwent allo-SCT. The high-risk (HR) group included those with t(4;11), t(8;14), low hypodiploidy, and complex karyotype, and the standard risk (SR) group included all other karyotypes. Among the 204 patients who underwent a transplant during the first remission (167 in the SR group and 37 in the HR group), the overall survival (OS) rates were similar between these groups (64.1% vs. 80.0% at 5 years, respectively; p = 0.12). Conversely, among the 106 patients who underwent a transplant while not in remission (84 in the SR group and 22 in the HR group), patients in the SR group showed a significantly superior OS rate compared to the HR group (15.4% vs. 4.5% at 5 years, respectively; p = 0.022). These results suggested that treatment outcomes of Ph-negative ALL patients with HR cytogenetic abnormalities may improve following allo-SCT, especially in the first remission. Innovative transplant approaches are warranted in patients who are not in remission.

AB - Although cytogenetic abnormalities at diagnosis are recognized as an important prognostic factor in patients with Philadelphia chromosome (Ph)-negative acute lymphoblastic leukemia (ALL), the prognostic impact has not been evaluated in allogeneic stem cell transplant (allo-SCT) recipients. Thus, we assessed 373 Ph-negative ALL patients who underwent allo-SCT. The high-risk (HR) group included those with t(4;11), t(8;14), low hypodiploidy, and complex karyotype, and the standard risk (SR) group included all other karyotypes. Among the 204 patients who underwent a transplant during the first remission (167 in the SR group and 37 in the HR group), the overall survival (OS) rates were similar between these groups (64.1% vs. 80.0% at 5 years, respectively; p = 0.12). Conversely, among the 106 patients who underwent a transplant while not in remission (84 in the SR group and 22 in the HR group), patients in the SR group showed a significantly superior OS rate compared to the HR group (15.4% vs. 4.5% at 5 years, respectively; p = 0.022). These results suggested that treatment outcomes of Ph-negative ALL patients with HR cytogenetic abnormalities may improve following allo-SCT, especially in the first remission. Innovative transplant approaches are warranted in patients who are not in remission.

UR - http://www.scopus.com/inward/record.url?scp=85066982210&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066982210&partnerID=8YFLogxK

U2 - 10.1038/s41409-019-0585-2

DO - 10.1038/s41409-019-0585-2

M3 - Article

AN - SCOPUS:85066982210

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

ER -